<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04460963</url>
  </required_header>
  <id_info>
    <org_study_id>AML2220</org_study_id>
    <nct_id>NCT04460963</nct_id>
  </id_info>
  <brief_title>Role of Adrenomedullin in Leukemic Endosteal/Vascular Niches</brief_title>
  <official_title>Role of Adrenomedullin in Leukemic Endosteal/Vascular Niches</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study will be divided into 5 phases:&#xD;
&#xD;
        1. Collection of bone marrow and peripheral blood (PB) samples from AML patients at&#xD;
           diagnosis;&#xD;
&#xD;
        2. Measurement of Midregional Proadrenomedullin (MR-proADM) plasma concentrations with an&#xD;
           Immunoluminometric Assay of newly diagnosed AML patients not affected by concomitant&#xD;
           cardiovascular disease or sepsis.&#xD;
&#xD;
        3. Analysis of exosomes and microvesicles derived from PB and bone marrow samples of AML&#xD;
           patients and culture media collected from AML samples stimulated with ADM and/or ADM&#xD;
           (22-52)&#xD;
&#xD;
        4. Study of adrenomedullin system in leukemic stem cells (CD44+/CD38-/CD31+/Lin-) in order&#xD;
           to define a correlated expression of ADM and ADM receptors (RAMPs, PAM) with adhesion&#xD;
           molecules (CD31, CD38, CD44s, CD44v6), cell cycle regulatory proteins (p21, p27) and&#xD;
           genes or molecules involved in the hematopoietic differentiation process (Cul5, CD11b,&#xD;
           CD11c, CD66, CD14, CD15, PML-RARÎ±)&#xD;
&#xD;
        5. In vitro evaluation of ADM activity in the growth, maturation and trans-endothelial&#xD;
           migration of blasts and/or fusion of leukemic cells with endothelial cells. To do this,&#xD;
           leukemic cells will be alternatively cultured by using in vitro models of endosteal and&#xD;
           vascular niches.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 9, 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of therapeutic potential of ADM inhibition on leukaemia stem cells</measure>
    <time_frame>at 1 year</time_frame>
    <description>Rate estimation of the in vitro arrest of leukemic blasts proliferation by ADM inhibition.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Biological evaluation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Adrenomedullin evaluation at diagnosis at first CR and 1 year of follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Adrenomedullin</intervention_name>
    <description>Adrenomedullin sample evaluation</description>
    <arm_group_label>Biological evaluation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with new diagnosis of primary or secondary AML.&#xD;
&#xD;
          2. Participant is willing and able to give signed written informed consent according to&#xD;
             ICH/EU/GCP and national local laws.&#xD;
&#xD;
          3. Male or Female, aged &gt;18 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients affected by concomitant cardiovascular disease , such as essential&#xD;
             hypertension (any grade), chronic renal failure (creatinine&gt;1.5 mg/dL), heart failure&#xD;
             (any NYHA class), and peripheral arterial occlusive diseases, or sepsis.&#xD;
&#xD;
          2. Patients affected by HIV, B or C hepatitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paola Fazi</last_name>
    <phone>0670390528</phone>
    <email>p.fazi@gimema.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enrico Crea</last_name>
    <phone>0670390514</phone>
    <email>e.crea@gimema.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>As Dell'Alto Adige, Ospedale Centrale Di Bolzano - Ematologia E Centro Trapianto Midollo Osseo</name>
      <address>
        <city>Bolzano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico Mosna</last_name>
      <phone>3404148772</phone>
      <email>federico.mosna@sabes.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.O. Oncoematologia IOV</name>
      <address>
        <city>Castelfranco Veneto</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Gottardi</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 25, 2020</study_first_submitted>
  <study_first_submitted_qc>July 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2020</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adrenomedullin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenomedullin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

